{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:26:29Z","timestamp":1782937589198,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.autrev.2011.07.001","type":"journal-article","created":{"date-parts":[[2011,7,21]],"date-time":"2011-07-21T16:35:17Z","timestamp":1311266117000},"page":"35-39","source":"Crossref","is-referenced-by-count":81,"title":["Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases"],"prefix":"10.1016","volume":"11","author":[{"given":"E.","family":"Miserocchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Pontikaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Modorati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gattinara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.L.","family":"Meroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gerloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2011.07.001_bb0005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaut.2007.02.001","article-title":"B cell targeted therapy in autoimmunity","volume":"28","author":"Blank","year":"2007","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.autrev.2011.07.001_bb0010","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.autrev.2005.04.004","article-title":"CD20: a target antigen for immunotherapy of autoimmune diseases","volume":"4","author":"Perosa","year":"2005","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2011.07.001_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2011.04.013","article-title":"B cells in systemic sclerosis: a possible target for therapy","author":"Bosello","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2011.07.001_bb0020","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.autrev.2006.02.007","article-title":"Treatment of rheumatoid arthritis with rituximab: an update and possible indications","volume":"5","author":"De Vita","year":"2006","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.autrev.2011.07.001_bb0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.autrev.2009.08.007","article-title":"International roundtable on B cells as therapeutic target for intervention. Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis","volume":"9","author":"D\u00f6rner","year":"2009","journal-title":"Autoimmun. Rev."},{"issue":"12","key":"10.1016\/j.autrev.2011.07.001_bb0030","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.autrev.2010.07.006","article-title":"Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today?","volume":"9","author":"Benucci","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2011.07.001_bb0035","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2011.07.001_bb0040","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2006.061002","article-title":"Consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"66","author":"Smolen","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2011.07.001_bb0045","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.autrev.2011.07.001_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2011.04.033","article-title":"A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection","author":"Visentini","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2011.07.001_bb0055","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.autrev.2006.02.014","article-title":"Potential adverse events with biologic response modifiers","volume":"5","author":"Kong","year":"2006","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2011.07.001_bb0060","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.autrev.2008.11.006","article-title":"Use of rituximab in systemic lupus erythematosus: an update","volume":"8","author":"Garcia-Carrasco","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2011.07.001_bb0065","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.autrev.2010.07.013","article-title":"Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: two sides of the same coin","volume":"9","author":"Conti","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2011.07.001_bb0070","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/kel098","article-title":"Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab","volume":"45","author":"Stasi","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2011.07.001_bb0075","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2796.2005.01494.x","article-title":"Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab","volume":"257","author":"Eriksson","year":"2005","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.autrev.2011.07.001_bb0080","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.autrev.2009.08.001","article-title":"B cell-targeted therapies in Sjogren's syndrome","volume":"9","author":"Tobon","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2011.07.001_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2009\/424935","article-title":"Controversies on Rituximab therapy in Sjogren syndrome-associated lymphoproliferation","volume":"10","author":"Quartuccio","year":"2009","journal-title":"Int. J. Rheumatol."},{"key":"10.1016\/j.autrev.2011.07.001_bb0090","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/09273940802331643","article-title":"Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis","volume":"16","author":"Onal","year":"2008","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.autrev.2011.07.001_bb0095","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/ard.2004.027128","article-title":"Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab","volume":"64","author":"Ai","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2011.07.001_bb0100","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1136\/bjo.2005.075689","article-title":"Successful treatment of Wegener's granulomatosis associated scleritis with rituximab","volume":"89","author":"Cheung","year":"2005","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.autrev.2011.07.001_bb0105","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24454","article-title":"Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis","volume":"60","author":"Taylor","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2011.07.001_bb0110","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/ard.2005.044420","article-title":"Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations","volume":"65","author":"Aries","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2011.07.001_bb0115","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/bjo.2007.133173","article-title":"Rituximab for treatment of ocular inflammatory disease: a series of four cases","volume":"93","author":"Kurz","year":"2009","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.autrev.2011.07.001_bb0120","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/bjo.2006.113316","article-title":"Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis","volume":"91","author":"Freidlin","year":"2007","journal-title":"Br. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.autrev.2011.07.001_bb0125","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/ICO.0b013e3181c296ed","article-title":"Rituximab for peripheral ulcerative keratitis with Wegener granulomatosis","volume":"29","author":"Huerva","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.autrev.2011.07.001_bb0130","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000103239","article-title":"Rituximab as a treatment option for refractory endogenous anterior uveitis","volume":"39","author":"Tappeiner","year":"2007","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.autrev.2011.07.001_bb0135","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study)","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.autrev.2011.07.001_bb0140","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s10165-008-0057-9","article-title":"Treatment of retinal vasculitis in Behcet's disease with rituximab","volume":"18","author":"Sadreddini","year":"2008","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.autrev.2011.07.001_bb0145","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/0961203309347332","article-title":"Bilateral retinal vasculitis in a patient with systemic lupus erythematosus and its remission with rituximab therapy","volume":"19","author":"Hickman","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2011.07.001_bb0150","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0896-8411(91)90004-V","article-title":"Bullous and cicatricial pemphigoid","volume":"4","author":"Anhalt","year":"1991","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.autrev.2011.07.001_bb0155","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid. A preliminary report","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2011.07.001_bb0160","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/sj.eye.6702804","article-title":"Intraocular use of rituximab","volume":"21","author":"Kitzmann","year":"2007","journal-title":"Eye"},{"key":"10.1016\/j.autrev.2011.07.001_bb0165","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1001\/archopht.126.7.1002","article-title":"Effect of intravitreous rituximab injections in patients with ocular lesions associated with central nervous system lymphoma","volume":"126","author":"Ohguro","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.autrev.2011.07.001_bb0170","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.ophtha.2006.05.016","article-title":"Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis","volume":"113","author":"Kump","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2011.07.001_bb0175","first-page":"1146","article-title":"Tumor necrosis factor-\u03b1 blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey","volume":"34","author":"Foeldvari","year":"2007","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.autrev.2011.07.001_bb0180","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2007.069484","article-title":"Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients","volume":"67","author":"Gerloni","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2011.07.001_bb0185","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/bjo.2007.124081","article-title":"Biological response modifier therapy for refractory childhood uveitis","volume":"91","author":"Gallagher","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.autrev.2011.07.001_bb0190","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1002\/art.24601","article-title":"Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis","volume":"60","author":"Barnes","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2011.07.001_bb0195","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ophtha.2010.07.031","article-title":"Rituximab for uveitis","volume":"118","author":"Miserocchi","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2011.07.001_bb0200","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.autrev.2011.07.001_bb0205","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"The standardization of uveitis nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first International workshop","volume":"140","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.autrev.2011.07.001_bb0210","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0161-6420(01)00864-8","article-title":"Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience","volume":"109","author":"Miserocchi","year":"2002","journal-title":"Ophthalmology"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997211001534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997211001534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T13:20:52Z","timestamp":1543670452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997211001534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S1568997211001534"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2011.07.001","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}